Can the Body's own immune cells beat a recurrent brain tumor?

NCT ID NCT01326104

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether giving patients their own tumor-specific immune cells, along with a dendritic cell vaccine, can help fight recurrent medulloblastoma or primitive neuroectodermal tumors. Participants receive these treatments after high-dose chemotherapy and a stem cell transplant. The goal is to see if this approach can improve progression-free survival at 12 months compared to historical benchmarks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Tumor-specific T cells (TTRNA-xALT) and dendritic cell vaccines (TTRNA-DCs)
What this could lead to
If successful, this approach could offer a new way to fight recurrent brain tumors in children, potentially improving survival and pointing toward a cure.
What could go wrong
This is an early-phase trial with a small number of patients, so results may not be conclusive. The treatment involves intensive chemotherapy and stem cell transplant, which carry significant risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MEDULLOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Children's Hospital Los Angeles

    Los Angeles, California, 90027, United States

  • Children's National Medical Center

    Washington D.C., District of Columbia, 20010, United States

  • University of Florida

    Gainesville, Florida, 32610, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.